We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cellular Biomedicine Group Inc | NASDAQ:CBMG | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 19.74 | 19.74 | 19.80 | 0 | 01:00:00 |
During this forum, CBMG's senior management team will discuss the Company's immuno-oncology cell therapy platform and clinical programs, including a comprehensive review of Phase I data on Chimeric Antigen Receptor T Cell (CAR-T) CD19 and CD20 that was previously released on March 25, 2015. In addition, there will also be a comprehensive review of the Phase IIb interim data on ReJoinTM human adipose-derived mesenchymal progenitor cell (haMPC) therapy for the treatment of Knee Osteoarthritis that was released on March 25, 2015. The event will feature presentations and question and answer sessions involving the principals leading CBMG's multiple ongoing and planned clinical studies. The session will be followed by a tour of CBMG's GMP facility and state-of-the-art research laboratories. "We look forward to reaffirming with our investors and strategic partners the business model we have created to become a world-class biotechnology firm focused on providing solutions to large unmet medical needs," commented Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group.
We have crafted an agenda based on feedback from our investors that will deliver the following key messages:
CLINICAL TRIALS
Please access the clinical trial details registered with the U.S. National Institute of Health (NIH) here:
ATTENDANCE AND PARTICIPATION
To register to attend the event, please email sarah.kelly@cellbiomedgroup.com.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility in China, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
CONTACT: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 sarah.kelly@cellbiomedgroup.com Vivian Chen Managing Director Investor Relations, Grayling +1 347 481-3711 vivian.chen@grayling.com
1 Year Cellular Biomedicine Chart |
1 Month Cellular Biomedicine Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions